Keywords: Merck & Co, Odanacatib, Osteoporosis, Ph III, Filing plans

Merck & Co closes odanacatib trial early on good results in osteoporosis

Article | 13 July 2012

Print This

US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in